A Peptide That's Scarcer in Alzheimer's Brains Cut Damage in Mice

Brain tissue from people who died with advanced Alzheimer's disease contains markedly less of a small peptide called catestatin than tissue from people without the disease — and when researchers gave the same peptide to mice bred to develop Alzheimer's-like pathology, the animals ended up with less tau tangling, less amyloid plaque, and memory and motor performance close to healthy mice.

The study, led by researchers at UC San Diego School of Medicine and the VA San Diego Healthcare System, was published September 21 in the journal Molecular Therapy (Jati et al., 2026). It's an early, mouse-stage finding, not a human treatment result — but it's a notably clean example of one peptide touching several of Alzheimer's separate biological problems at once, which is unusual enough that it's worth walking through both what was found and how far it is from meaning anything for people.

What the researchers found

Catestatin (CST) isn't new to science. It's a fragment cut from a larger protein called chromogranin A, and it was already known to dial down the release of adrenaline-family stress hormones and to play a role in blood pressure and insulin sensitivity. What's new here is where else it showed up.

The team compared donated human brain tissue from advanced Alzheimer's cases (rated Braak stage 6, the most severe tissue-damage classification) against tissue from people with little or no disease pathology (Braak stage 0–2), and found significantly less catestatin in the Alzheimer's group, in both the prefrontal cortex and the hippocampus/entorhinal cortex — the memory-forming regions Alzheimer's hits hardest. Catestatin levels also tracked with how impaired the donors had been: higher levels lined up with better scores on the Mini-Mental State Examination, a standard cognitive test, in both brain regions (statistically significant correlations, p = 0.0008 and p = 0.0047). The same pattern — less catestatin with more disease — showed up in brain tissue from two rarer neurodegenerative disorders, corticobasal degeneration and progressive supranuclear palsy, suggesting the drop isn't unique to Alzheimer's.

That part of the study is observational: it shows catestatin is low where damage is high, not that the shortage causes the damage. The mouse work is where the researchers tested that directly. Using two standard lab models — mice engineered to accumulate misfolded tau, and separate mice engineered to accumulate amyloid plaques — they gave one group of animals catestatin over several months and compared them to untreated animals of the same strain. The treated mice had roughly 42–46% more hippocampal volume than untreated ones (a proxy for less tissue loss), significantly less of the misfolded tau marker MC1, a smaller area covered by amyloid plaques, and less microglial activation, a marker of brain inflammation. On behavioral tests — a maze task, grip strength, a rotating rod — the catestatin-treated mice performed close to mice that had no disease-causing mutation at all, while untreated diseased mice performed worse.

Why one peptide would touch that many pathways

The mechanism the paper proposes is adrenergic: catestatin's known job is suppressing the release of epinephrine and norepinephrine, and dampening a signaling chain called cAMP–PKA that those stress hormones switch on inside cells. That chain matters here because PKA is one of the enzymes that adds phosphate groups to the tau protein — a modification that is a required first step before tau misfolds and clumps into the tangles seen in Alzheimer's tissue. In the mice, catestatin suppressed that PKA activity, and tau phosphorylation and tangling dropped alongside it.

That single mechanism doesn't obviously explain the amyloid and inflammation findings too, and the paper's senior author, Sushil K. Mahata, frames the appeal of the molecule as its breadth rather than a single clean pathway: "Neurodegenerative diseases involve multiple interconnected problems — including misfolded proteins, neuroinflammation and progressive dysfunction of brain cells. Our findings show that CST can act across several of these disease-associated pathways and shift the brain toward a healthier state," he said, according to UC San Diego's research office. The team is separately looking at whether catestatin also changes how brain cells produce and use energy, which would be a third pathway on top of the two this paper already reports.

What's actually established versus what isn't

The honest read of this study has two very different levels of evidence sitting inside it. The human brain-tissue comparison is real human data, but it's a snapshot of donated tissue after death, from a relatively small number of brains (16 Alzheimer's cases, 14 controls, for the main comparison) — it can show an association, not a cause. The interventional result — giving catestatin and watching pathology drop — is the stronger kind of evidence, but it happened entirely in genetically engineered mice, over months, not in people. Mouse models of Alzheimer's are deliberately built to overproduce tau or amyloid in ways human disease doesn't cleanly replicate, and a result that holds up in mice frequently doesn't survive the jump to human trials. A recent review the Journal covered found that two-thirds of the peptide studies it surveyed were animal-only for exactly this reason — the translation step is where most peptide research stalls, and there's no reason to assume this one is different until it's tested.

The paper itself doesn't claim otherwise. Getting from here to a human study means, at minimum, establishing that catestatin can be delivered into the human brain in the first place — a molecule this size doesn't cross the blood-brain barrier on its own — plus standard safety and dosing work that hasn't started. The research was funded by the National Institutes of Health and the U.S. Department of Veterans Affairs, with no pharmaceutical company involved yet.

What this means for researchers

What makes this study worth tracking isn't a single number — it's the shape of the result. Most experimental Alzheimer's compounds are built to hit one target: clear amyloid, or block a specific tau-modifying enzyme. Catestatin showed up in this paper touching three separately measured problems — tau, amyloid and inflammation — through what the authors argue is one upstream mechanism. If that holds up under independent replication, it would be a genuinely different kind of drug candidate than the amyloid-clearing antibodies currently approved.

It also holds up as an example of why the human and animal halves of a paper like this need to be read as different categories of evidence, not one continuous story. The correlation in donated brain tissue is suggestive; the intervention in mice is a real causal test, but of a mouse model of the disease, not the disease itself. Readers who want to track this one forward should watch for whether an independent lab reproduces the mouse results, and for any published work on getting catestatin — or a modified version of it — across the blood-brain barrier in a living brain, since that engineering problem, not the biology, is likely to be the next bottleneck. A general primer on how peptides like this move from bench to (eventual, if ever) clinic is on Learn.